Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

华昊中天
Biostar

Beijing Biostar Pharmaceuticals Co., Ltd.
北 京 華 昊 中 天 生 物 醫 藥 股 份 有 限 公 司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2563)

VOLUNTARY ANNOUNCEMENT

Reference is made to the announcement of Beijing Biostar Pharmaceuticals Co., Ltd. (the "**Company**") dated 1 December 2025 (the "**Announcement**") regarding the redemption of subscriptions to the LFM Stable Income Fund SP. Unless otherwise defined herein or the context requires, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Grand Court of the Cayman Islands (Financial Services Division) (the "**Court**") rendered its judgment on 3 December 2025, approving the Company's application to appoint a receiver over the Sub-Fund. The Court found that US-Biostar was a creditor based on the terms of the subscription letter.

The Company's Legal Counsel has already communicated with the appointed receiver (the "**Receiver**"), who will initiate the winding-up petitions and receivership proceedings of the LFM Fund in accordance with the laws of the Cayman Islands. The Company contacted the Receiver on 10 December 2025 to advance the receivership process.

The Company will publish further announcement(s) as and when appropriate to inform the Shareholders and potential investors in the event that there are any material updates in relation to the above.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairperson and Executive Director

Beijing, the PRC, 11 December 2025

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Dr. Meng Songdong, Mr. Shiu Shu Ming and Dr. Ye Chengang as independent non-executive Directors.